ABSTRACT NUMBER: ESOC2026A341 ARGATROBAN PLUS ANTIPLATELET THERAPY VERSUS ANTIPLATELET ALONE IN ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS WITH GRADE ASSESSMENT Authors: Ahmed W Abbas, Rashad G Mohamed, Yousef Hawas, Mohamed Ellebedy, Mohamed F Abo-Elsoad, Magdy Shehab, Amir Hegazi, Hussien Hussien, Sarah Amro, Kareem Khalefa, Moaz Abouelmagd, Muataz Kashbour Published: 2026 ABSTRACT AbstractBackground and aimsAlthough antiplatelet therapy is commonly used, its effectiveness is limited. Argatroban, a direct thrombin inhibitor, offers potential benefits for AIS patients. This meta-analysis compares the efficacy and safety of combining argatroban with antiplatelet therapy versus antiplatelet therapy alone.MethodsPubMed, Scopus, Cochrane, and Web of Science were searched up to May 5, 2025. Primary outcomes included the modified Rankin Scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS). Secondary outcomes included early neurological deterioration (END) and safety outcomes.Results18 studies with a total of 11,781 patients were included in our study. Combined therapy significantly improved functional outcomes: mRS 0-2 (RR = 1.07, 95% CI [1.03–1.11], p = 0.001) and mRS 0-1 (RR = 1.21, 95% CI [1.06–1.38], p = 0.004). Argatroban also reduced the risk of END (RR = 0.49, 95% CI [0.32–0.76], p = 0.001) and overall NIHSS scores (MD = -0.55, 95% CI [-0.99 to -0.10], p = 0.02). No significant differences were found in safety outcomes or mortality.ConclusionsArgatroban combined with antiplatelet therapy enhances neurological and functional recovery in AIS without elevating bleeding or mortality risks. This dual approach shows promise as a treatment strategy, though larger randomized trials are needed to validate its benefits.Conflict of interestAll Authors have nothing to disclose